TissueCypher Barrett’s esophagus assay impacts clinical decisions in the management of patients with Barrett’s esophagus
Open Access
- 18 February 2021
- journal article
- research article
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 09 (03), E348-E355
- https://doi.org/10.1055/a-1326-1533
Abstract
Background and study aims The TissueCypher Barrett’s Esophagus Assay is a novel tissue biomarker test, and has been validated to predict progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with Barrett’s esophagus (BE). The aim of this study was to evaluate the impact of TissueCypher on clinical decision-making in the management of BE. Patients and methods TissueCypher was ordered for 60 patients with non-dysplastic (ND, n = 18) BE, indefinite for dysplasia (IND, n = 25), and low-grade dysplasia (LGD, n = 17). TissueCypher reports a risk class (low, intermediate or high) for progression to HGD or EAC within 5 years. The impact of the test results on BE management decisions was assessed. Results Fifty-two of 60 patients were male, mean age 65.2 ± 11.8, and 43 of 60 had long segment BE. TissueCypher results impacted 55.0 % of management decisions. In 21.7 % of patients, the test upstaged the management approach, resulting in endoscopic eradication therapy (EET) or shorter surveillance interval. The test downstaged the management approach in 33.4 % of patients, leading to surveillance rather than EET. In the subset of patients whose management plan was changed, upstaging was associated with a high-risk TissueCypher result, and downstaging was associated with a low-risk result (P < 0.0001). Conclusions TissueCypher was used as an adjunct to support a surveillance-only approach in 33.4 % of patients. Upstaging occurred in 21.7 % of patients, leading to therapeutic intervention or increased surveillance. These results indicate that the TissueCypher test may enable physicians to target EET for TissueCypher high-risk BE patients, while reducing unnecessary procedures in TissueCypher low-risk patients. Received: 30 July 2020 Accepted: 21 October 2020 Publication Date: 18 February 2021 (online) © 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyThis publication has 33 references indexed in Scilit:
- TissueCypher™: A systems biology approach to anatomic pathologyJournal of Pathology Informatics, 2015
- Association Between Length of Barrett's Esophagus and Risk of High-grade Dysplasia or Adenocarcinoma in Patients Without DysplasiaClinical Gastroenterology and Hepatology, 2013
- The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysisBreast Cancer Research and Treatment, 2013
- The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysisGut, 2011
- American Gastroenterological Association Technical Review on the Management of Barrett's EsophagusGastroenterology, 2011
- Patients With Nondysplastic Barrett's Esophagus Have Low Risks for Developing Dysplasia or Esophageal AdenocarcinomaClinical Gastroenterology and Hepatology, 2011
- American Gastroenterological Association Medical Position Statement on the Management of Barrett's EsophagusGastroenterology, 2011
- The Perception of Cancer Risk in Patients With Prevalent Barrett’s Esophagus Enrolled in an Endoscopic Surveillance ProgramGastroenterology, 2005
- The Perception of Cancer Risk in Patients With Prevalent Barrett’s Esophagus Enrolled in an Endoscopic Surveillance ProgramGastroenterology, 2005
- Reproducibility of the diagnosis of dysplasia in Barrett esophagus: A reaffirmationHuman Pathology, 2001